Codelivery of an antifungal drug within antifungal micelles achieves effective combinatorial therapy.

This unique, collaborative book, featuring contributions from autistic and non-autistic experts, presents cutting-edge thinking on mental health and service transformation in relation to autistic chil...

Read the full paper: Development of a Synergistic Photothermal-Immunotherapy Nanoplatform via Codelivery of a STING Agonist and Cyanine Dye against Triple-Negative Breast Cancer

Read the full paper: The Enhanced Whey Protein Oral Bioavailability and Muscle Anabolism Ability by a Simple and Effective Piperine‐Whey Protein Synergistic Codelivery System

WP(Pip) is a mixture of whey protein and piperine-loaded nanoemulsion stabilized by WP through microfluidic homogenization. Acting as a “smart key,” piperine opens epithelial tight junctions to enhan....

Pancreatic ductal adenocarcinoma is a highly aggressive cancer with a low survival rate. Thus, efforts are needed to develop more effective treatments…

Neuroinflammation induced by the accumulation of amyloid beta plaques expedites the progression of Alzheimer’s disease (AD). Reducing Aβ plaques and associated neuroinflammation could potentially help to delay the progression of AD. Cannabidiol (CBD) is well-known for its antioxidant, anti-inflammatory, and neuroprotective nature, and the ApoE2 is effective in binding and clearing Aβ plaques in the brain. Therefore, codelivery of CBD and pApoE2 to the brain would be a promising therapeutic approach in developing effective therapeutics against AD. This research aims to design a nonviral delivery agent that delivers both drugs and genes to the brain through a noninvasive intranasal route. We have developed mPEG–PLGA nanoparticles coated with mannose, a brain-targeting ligand, to deliver CBD and pApoE2. The designed CBD-loaded coated nanoparticles showed an average diameter of 179.3 ± 4.57 nm and a zeta potential of 30.3 ± 6.45 mV. The coated nanoparticles prolonged the CBD release and showed a 93% release of its payload in 30 days. CBD-loaded nanoparticles, as compared to the free CBD, significantly reduced lipopolysaccharide and amyloid beta-induced inflammation in immortalized microglia cells. Cytotoxicity of the designed nanoparticles was assessed against brain endothelial cells (bEND.3) and found to be nontoxic in nature. The mannose-conjugated chitosan-coated nanoparticles were cationic and able to bind with the pApoE2, protecting the encapsulated pApoE2 from enzymatic degradation. Quantitative in vitro transfection efficiency study in primary astrocytes and primary neurons revealed that the ApoE2 expression level is significantly (P < 0.0001) higher for mPLGA-CBD-MC/pApoE2 than the control. The ApoE2 expression level in the brain of C57BL6/J mice was significantly (P < 0.0001) increased after intranasal administration of mPLGA-CBD-MC/pApoE2. Henceforth, the mannose-conjugated chitosan-coated mPLGA nanoparticles could serve as a nonviral delivery system to deliver both drugs and genes to the brain through the intranasal route for the management of AD.

Computational analysis guides design of ionizable drug–RNA lipid nanoparticle formulations, exemplified by netarsudil and siCTGF.

Glycerol may boost nasal delivery of dual antibodies to treat melanoma brain metastases effectively.

Codelivery of an antifungal drug within antifungal micelles achieves effective combinatorial therapy.

Lipid nanoparticle codelivery of an oligonucleotide-based cGAS agonist (Svg3) and peptide or mRNA vaccines was developed for adjuvant/antigen codelivery to draining lymph nodes and intranodal APCs, where Svg3 activated cGAS to elicit IFN-I responses and hence potentiate antitumor T cell response. As a result, this promoted tumor combination therapeutic efficacy.